{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:37:32Z","timestamp":1773967052410,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.brachy.2025.12.002","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T20:36:35Z","timestamp":1767645395000},"page":"306-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-103"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-5107","authenticated-orcid":false,"given":"Martin","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grgur","family":"Miri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-0951","authenticated-orcid":false,"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4266-2191","authenticated-orcid":false,"given":"Robert","family":"Galbreath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Fiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2610-9210","authenticated-orcid":false,"given":"Kent","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Orio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.brachy.2025.12.002_bib0001","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.brachy.2021.07.006","article-title":"Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement","volume":"20","author":"King","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2025.12.002_bib0002","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. Version 2.2025. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed July 12, 2025."},{"issue":"1","key":"10.1016\/j.brachy.2025.12.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/0360-3016(92)90546-T","article-title":"Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model","volume":"23","author":"Ling","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.brachy.2025.12.002_bib0004","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0360-3016(03)01448-2","article-title":"125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial","volume":"57","author":"Wallner","year":"2003","journal-title":"Int J Radiat Oncol"},{"issue":"4","key":"10.1016\/j.brachy.2025.12.002_bib0005","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.juro.2007.11.061","article-title":"Mayo Clinic validation of the D\u2019Amico risk group classification for predicting survival following radical prostatectomy","volume":"179","author":"Boorjian","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2025.12.002_bib0006","unstructured":"Merrick G. Pd-103 dose de-escalation for early stage prostate cancer: a prospective randomized trial. Clinicaltrials.Gov; 2015. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00247312. Accessed November 23, 2025."},{"issue":"2","key":"10.1016\/j.brachy.2025.12.002_bib0007","first-page":"152","article-title":"Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry","volume":"18","author":"Dicker","year":"2000","journal-title":"Semin Urol Oncol"},{"issue":"3","key":"10.1016\/j.brachy.2025.12.002_bib0008","first-page":"233","article-title":"Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation","volume":"7","author":"Merrick","year":"2001","journal-title":"Tech Urol"},{"issue":"6","key":"10.1016\/j.brachy.2025.12.002_bib0009","first-page":"592","article-title":"Prognostic significance of prostate cancer originating from the transition zone","volume":"27","author":"King","year":"2009","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.brachy.2025.12.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109599","article-title":"Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: an international, multi-institutional study","volume":"183","author":"Tang","year":"2023","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.002_bib0011","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2017.10.008","article-title":"Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: substantiation of the rationale for focal therapy","volume":"17","author":"Ferro","year":"2018","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.brachy.2025.12.002_bib0013","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG Oncology RTOG 0415: a randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.brachy.2025.12.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.brachy.2025.12.002_bib0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.002_bib0016","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.juro.2018.08.047","article-title":"Genomic prostate score, PI-RADSTM version 2 and progression in men with prostate cancer on active surveillance","volume":"201","author":"Kornberg","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2025.12.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003396","article-title":"Impact of an expanded definition of Family history on outcomes of active surveillance for prostate cancer","author":"Schneider","year":"2023","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.brachy.2025.12.002_bib0018","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1002\/cncr.31568","article-title":"Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer","volume":"124","author":"King","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.brachy.2025.12.002_bib0019","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.brachy.2024.01.011","article-title":"Focal brachytherapy as definitive treatment for localized prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Mohamad","year":"2024","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.60785","article-title":"Race and ethnicity, lifestyle, diet, and survival in patients with prostate cancer","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153847212500368X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153847212500368X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:39:16Z","timestamp":1773959956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153847212500368X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S153847212500368X"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.12.002","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-103","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Brachytherapy Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}